Shares of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) were down 3.4% during mid-d

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'

Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re

Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-mar

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Redu

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Redu

Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Acad

Telomir wins FDA IND clearance for Telomir-Zn in TNBC, enabling a Phase 1/2 study targeting epigenet

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) shares traded up 1.4% during trading

Transaction establishes global ownership rights of lead program and includes initial capital funding

Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) and Jaguar Animal Health (NASDAQ: JAGX - Ge

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechn

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinica

Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cyto

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress,

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress,

Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) is expected to be issuing its results befor

electroCore (NASDAQ: ECOR - Get Free Report) and Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Re

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistic

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) was down 8.9% on Monday. The stock tr

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent sys

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response;

Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reporte

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicro

New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell

Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the

Editor’s Note: The future prices of benchmark tracking ETFs and lede were updated in the story.)

TMQ: 230% | Shares of mining companies that operate in Alaska are trading higher after President Tru

U.S. stock futures mixed, key stocks to watch: MKC, SNWV, PENG, TELO, SAR. Check out premarket cover

U.S. stock futures were swinging on Thursday following Wednesday's advances. Futures of major be